GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CAS Medical Systems Inc (NAS:CASM) » Definitions » ROE %

CAS Medical Systems (CAS Medical Systems) ROE % : 0.00% (As of Dec. 2018)


View and export this data going back to 1995. Start your Free Trial

What is CAS Medical Systems ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CAS Medical Systems's annualized net income for the quarter that ended in Dec. 2018 was $-6.18 Mil. CAS Medical Systems's average Total Stockholders Equity over the quarter that ended in Dec. 2018 was $-1.59 Mil. Therefore, CAS Medical Systems's annualized ROE % for the quarter that ended in Dec. 2018 was N/A%.

The historical rank and industry rank for CAS Medical Systems's ROE % or its related term are showing as below:

CASM's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.31
* Ranked among companies with meaningful ROE % only.

CAS Medical Systems ROE % Historical Data

The historical data trend for CAS Medical Systems's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CAS Medical Systems ROE % Chart

CAS Medical Systems Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -120.72 -156.38 -69.73 -78.87 -4,768.80

CAS Medical Systems Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -187.64 -284.31 -863.98 - -

Competitive Comparison of CAS Medical Systems's ROE %

For the Medical Instruments & Supplies subindustry, CAS Medical Systems's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CAS Medical Systems's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CAS Medical Systems's ROE % distribution charts can be found below:

* The bar in red indicates where CAS Medical Systems's ROE % falls into.



CAS Medical Systems ROE % Calculation

CAS Medical Systems's annualized ROE % for the fiscal year that ended in Dec. 2018 is calculated as

ROE %=Net Income (A: Dec. 2018 )/( (Total Stockholders Equity (A: Dec. 2017 )+Total Stockholders Equity (A: Dec. 2018 ))/ count )
=-5.961/( (2.513+-2.263)/ 2 )
=-5.961/0.125
=-4,768.80 %

CAS Medical Systems's annualized ROE % for the quarter that ended in Dec. 2018 is calculated as

ROE %=Net Income (Q: Dec. 2018 )/( (Total Stockholders Equity (Q: Sep. 2018 )+Total Stockholders Equity (Q: Dec. 2018 ))/ count )
=-6.18/( (-0.92+-2.263)/ 2 )
=-6.18/-1.5915
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2018) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


CAS Medical Systems  (NAS:CASM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2018 )
=Net Income/Total Stockholders Equity
=-6.18/-1.5915
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.18 / 23.208)*(23.208 / 11.292)*(11.292 / -1.5915)
=Net Margin %*Asset Turnover*Equity Multiplier
=-26.63 %*2.0553*N/A
=ROA %*Equity Multiplier
=-54.73 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2018 )
=Net Income/Total Stockholders Equity
=-6.18/-1.5915
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-6.18 / -6.18) * (-6.18 / -4.972) * (-4.972 / 23.208) * (23.208 / 11.292) * (11.292 / -1.5915)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.243 * -21.42 % * 2.0553 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2018) net income data. The Revenue data used here is four times the quarterly (Dec. 2018) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


CAS Medical Systems ROE % Related Terms

Thank you for viewing the detailed overview of CAS Medical Systems's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CAS Medical Systems (CAS Medical Systems) Business Description

Traded in Other Exchanges
N/A
Address
44 East Industrial Road, Branford, CT, USA, 06405
CAS Medical Systems Inc is a medical technology company that develops, manufactures, and markets non-invasive patient monitoring products. The company's products are the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. .
Executives
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Thomas M Patton director, officer: President and CEO C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Kenneth R Weisshaar director 875 PARK AVE APT 2D, NEW YORK NY 10021
James E Thomas director, 10 percent owner WOODS END ROAD, NEW CANAAN CT 06840
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Acuta Capital Fund, Lp 10 percent owner 1301 SHOREWAY ROAD, SUITE 350, BELMONT CA 94002
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Lawrence Burstein director C/O UNITY VENTURE CAPITAL ASSOCIATES LTD, 245 FIFTH AVENUE, SUITE 1500, NEW YORK NY 10016

CAS Medical Systems (CAS Medical Systems) Headlines

From GuruFocus